top of page
Sage Group News
Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody
Starrygene ( https://www.starrygene.com/ ) is a clinical stage biotechnology company based in China, focused on XMVA09, a novel...
Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)
Serpin Pharma (“Serpin”) is an anti-inflammatory/immunology company focused on developing its patented (CoM and use) SP-16 LRP1 agonist...
Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors
Our client, Starmab Biomed Inc (“Starmab” or the “Company”), is a US/China-based biotech company headquartered at Beijing Zhongguancun...
Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells
Zumutor Biologics is a biotechnology company based in Boston, USA, and Bangalore, India, focused on advancing innovative cancer...
D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner
Our client, PolyPid Ltd. ( PolyPid - Optimized Therapeutics ; NASDAQ:PYPD) has a patented surgical site infection (SSI) prevention...
Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification
Evecxia deploys 5-hydroxytryptophan, 5-HTP, to achieve Serotonin Synthesis Amplification. 5-HTP amplifies brain serotonin and have shown...
The Sage Group: 30 Years of Successful Bioscience Transactions
London and New York, September 1 2024 - The Sage Group ( www.sagehealthcare.com ), a leading global advisor in the bioscience sector,...
Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)
Our client, Coagulant Therapeutics Corporation (CTC), is developing a novel, patented (4 families due to expire 2041-2043 period)...
bottom of page